{
    "clinical_study": {
        "@rank": "127679", 
        "arm_group": [
            {
                "arm_group_label": "QBECO", 
                "arm_group_type": "Experimental", 
                "description": "Individualized maintenance dose ranging from 0.01 - 0.2 mL, administered subcutaneously, every other day for a maximum of 16 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Individualized maintenance dose ranging from 0.01 - 0.2 mL, administered subcutaneously, every other day for a maximum of 16 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety profile and to obtain an indication as\n      to the therapeutic effect of QBECO induction treatment on clinical improvement in moderate\n      to severe Crohn's Disease."
        }, 
        "brief_title": "Safety and Treatment Effect of QBECO in Moderate to Severe Crohn's Disease", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Crohn's Disease", 
            "Inflammatory Bowel Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Crohn Disease", 
                "Inflammatory Bowel Diseases", 
                "Intestinal Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  An adult, age 18 and above\n\n          -  Diagnosed with Crohn's disease AT LEAST six (6) months prior to screening\n\n          -  Crohn's disease diagnosis was verified by one of these procedures: 1) Colonoscopy 2)\n             Capsule endoscopy 3) Computed Tomography (CT) scan 4) Magnetic Resonance Imaging\n             (MRI) 5) Ultrasound\n\n          -  Active Crohn's disease at the time of screening\n\n          -  Female participants: Agree to practice two effective methods of contraception, at the\n             same time, from the time of signing the informed consent form, during the entire\n             study treatment and for two (2) months after taking the last dose of study treatment.\n\n          -  Male participants: Agree to practice effective barrier contraception during the\n             entire study treatment period and for two (2) months after taking the last dose of\n             study treatment.\n\n        Exclusion Criteria:\n\n          -  Currently pregnant or breastfeeding\n\n          -  Have known or suspected hypersensitivity to any component of the product\n\n          -  Had more than three (3) small bowel resections or diagnosis of short bowel syndrome\n\n          -  Currently anticipate undergoing any major surgical intervention for Crohn's disease\n             during the next six (6) months\n\n          -  Previously been treated with any Qu Biologics' Site Specific Immunomodulators (SSIs)\n             for any disease\n\n          -  Diagnosed with chronic (i.e., long term) hepatitis B or C infection\n\n          -  Diagnosed with congenital (i.e., existing at or before birth) or acquired\n             immunodeficiency (i.e., lack of body defense system). For example, human\n             immunodeficiency virus (HIV) infection, organ transplantation (i.e., specifically\n             received an organ from a donor), etc.\n\n          -  Daily use of narcotic drugs containing opiates (such as morphine, codeine, etc.) for\n             pain control\n\n          -  Have a current or recent history (within the past 12 months) of alcohol dependence or\n             illicit drug use, with the exception of medicinal marijuana prescribed by a physician\n\n          -  Have a history of cancer within the last five (5) years. Exceptions may apply for\n             cervical cancer and some forms of skin cancer"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01809275", 
            "org_study_id": "QBECO-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "QBECO", 
                "intervention_name": "QBECO", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Crohn's Disease", 
            "Inflammatory Bowel Disease", 
            "CDAI"
        ], 
        "lastchanged_date": "April 11, 2013", 
        "link": {
            "description": "Informational website for this trial", 
            "url": "http://www.qucrohnstrial.com"
        }, 
        "location": {
            "contact": {
                "last_name": "Juliet Luna-Algoso", 
                "phone": "6046886332", 
                "phone_ext": "288"
            }, 
            "facility": {
                "address": {
                    "city": "Vancouver", 
                    "country": "Canada", 
                    "state": "British Columbia", 
                    "zip": "V6Z 2K5"
                }, 
                "name": "Gastrointestinal Research Institute"
            }, 
            "investigator": {
                "last_name": "Brian Bressler, MD, FRCPC", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1/2 Randomized, Placebo-Controlled, Double-Blind Study of the Induction of Clinical Response and Remission by QBECO in Subjects With Moderate to Severe Crohn's Disease", 
        "overall_contact": {
            "email": "qucrohnstrial@qubiologics.com", 
            "last_name": "Winnie Lim", 
            "phone": "6047341450"
        }, 
        "overall_official": [
            {
                "affiliation": "Gastrointestinal Research Institute", 
                "last_name": "Brian Bressler, MD, FRCPC", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Qu Biologics Inc.", 
                "last_name": "Simon Sutcliffe, MD, FRCP, FRCPC, FRCR", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Assessing adverse events, concomitant therapies, clinical chemistry, hematology, urinalysis chemistry", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Assessing the change in Crohn's Disease Activity Index (CDAI) from baseline", 
                "measure": "Clinical improvement", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01809275"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Assessing the change in Crohn's Disease Activity Index (CDAI) from baseline", 
                "measure": "Clinical remission", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Assessing the change in Crohn's Disease Activity Index (CDAI) from baseline", 
                "measure": "Clinical response", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Assessing the change in fecal calprotectin from baseline", 
                "measure": "Intestinal inflammation", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Assessing the change in C-reactive protein (CRP) from baseline", 
                "measure": "Systemic inflammation", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "source": "Qu Biologics Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Qu Biologics Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}